Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease
Por:
Vallderiola F, Compta Y, Aparicio J, Tarradellas J, Salazar G, Oliver JM, Callen A, Delgado T and Nobbe F
Publicada:
1 ene 2015
Categoría:
Psychiatry and Mental Health
Resumen:
Objectives. This open-label study assessed the efficacy and safety of exclusive night-time administration of transdermal rotigotine in patients with nocturnal and early morning PD symptoms. Methods. Patients with PD and nocturnal and early morning symptoms received transdermal rotigotine patches (2-16 mg/24 h) applied in the evening and removed in the morning for 3 months. Sleep disturbance was assessed with modified Parkinson's Disease Sleep Scale (PDSS-2). Other outcomes included a pain visual analogue scale (VAS) and short-form Parkinson's Disease Questionnaire (PDQ-8) for quality of life. Results. 74 patients completed treatment in this study. At the end of treatment, PDSS-2 total score had improved by mean 10.9 points from baseline (p < 0.001). All three PDSS-2 domain scores (sleep disturbances, nocturnal motor symptoms, and nocturnal symptoms) were also significantly improved by 41%, 56%, and 48%, respectively (p < 0.001). VAS-pain score decreased from 3.2 to 2.3 (p < 0.001). PDQ-8 score decreased from 23.8 to 18.1 (p < 0.001). The most frequently reported adverse events included nausea (9%), anxiety (4%), and dizziness (4%). Conclusions. Night-time administration of transdermal rotigotine is an effective and well tolerated treatment for nocturnal symptoms in patients with PD.
Filiaciones:
Vallderiola F:
Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain
Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Catalonia, Spain
Compta Y:
Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain
Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Catalonia, Spain
Tarradellas J:
Neurology Service, Clínica Dexeus, Barcelona, Catalonia, Spain
Salazar G:
Neurology Service, Hospital de Terrassa, Barcelona, Catalonia, Spain
Oliver JM:
Cap Clìnic de Neurologìa, Hospital Universitario Reus and Department of Medicine and Surgery, Universitat de Tarragona, Tarragona, Catalonia, Spain
Callen A:
Neurology Service, Parc Sanitari Sant Joan de Déu, Sant Boi, Barcelona, Catalonia, Spain
Delgado T:
Neurology Service, Hospital Parc Taulí de Sabadell, Catalonia, Spain
Nobbe F:
Clínica Juaneda, Palma de Mallorca, Balearic Islands, Spain
Epilepsy Unit, Department of Neurology, Hospital Clínic, Barcelona, Catalonia, Spain
Open Access
|